


Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 3

This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound of Formula I:



wherein

$R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are independently

H,

HO,

$R^{13}O-$ ,

$R^{13}S-$ ,

halogen,

C1-C3-alkyl,

Attorney Docket No.:  
Inventors:  
Serial No.:  
Filing Date:  
Page 4

SYM114 (TI-0029)  
Pei et al.  
09/882,843  
June 15, 2001

$\text{CF}_3$ ,

$\text{R}^{14}\text{CO}_2^-$ ,

$\text{R}^{14}\text{O}_2\text{C}-$ ,

$\text{R}^{14}\text{CO}-$

$\text{R}^{14}\text{CONH}-$ ,

$\text{R}^{14}\text{NHCO}-$ ,

$\text{R}^{14}\text{NHCO}_2^-$ ,

$\text{R}^{14}\text{OCONH}-$ ,

$\text{R}^{14}\text{O}_2\text{S}-$ ,

$\text{R}^{14}\text{OS}-$ , or

$\text{R}^{15}\text{R}^{16}\text{N}-$ ; or

$\text{R}^1$  and  $\text{R}^2$ , or  $\text{R}^2$  and  $\text{R}^3$ , or  $\text{R}^3$  and  $\text{R}^4$  taken together can be

$-\text{SCH}_2\text{S}-$ ,

$-\text{SCH}_2\text{O}-$ ,

$-\text{OCH}_2\text{S}-$ ,

$-\text{SCH}_2\text{CH}_2\text{S}-$ ,

$-\text{SCH}_2\text{CH}_2\text{O}-$ , or

$-\text{OCH}_2\text{CH}_2\text{S}-$ ;

wherein one of  $\text{R}^1$ ,  $\text{R}^3$  and  $\text{R}^4$  must be C1-C3-alkoxy or C1-C3-alkylthio group;

$\text{R}^5$ ,  $\text{R}^6$ ,  $\text{R}^7$  and  $\text{R}^8$  are independently

H,

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 5

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen,  $R^{13}O-$ ,  $CF_3-$ ,  $R^{14}O_2S-$ ,  $R^{14}OS-$ ,  $R^{14}CO-$ ,  $R^{14}CO_2-$ ,  $R^{14}O_2C-$ ,  $R^{14}CONH-$ ,  $R^{14}NHCO-$ ; or

$R^5$  and  $R^6$  taken together can be C3-C6-cycloalkyl;

$R^7$  and  $R^8$  taken together can be C3-C6-cycloalkyl;

$R^9$  is

$R^{15}R^{16}NCO-$ ,

$R^{15}R^{16}NCS-$ ,

$R^{15}R^{16}N(CR^{17})-$ ,

$R^{17}OCO-$ ,

$R^{15}CO-$ ,

$R^{15}R^{16}NCH_2CO-$ ,

$R^{14}O_2C-(CH_2)_n-$ ,

$R^{15}R^{16}NCO-(CH_2)_n-$ ,

$NC-(CH_2)_n-$ ,

H,

C1-C6-alkyl,

C3-C6-alkenyl, or

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 6

C3-C6-cycloalkyl; or

R<sup>8</sup> and R<sup>9</sup> taken together can be

- (CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>(R<sup>15</sup>)NCO-,

- (CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>OCO-, or

- (CH<sub>2</sub>)<sub>m</sub>CH<sub>2</sub>CH<sub>2</sub>CO-;

R<sup>10</sup> and R<sup>11</sup> are independently

H,

R<sup>15</sup>R<sup>16</sup>N-,

~~R<sup>15</sup>R<sup>16</sup>N(CR<sup>17</sup>)-~~

R<sup>14</sup>HNCO-, or

R<sup>14</sup>CONH-;

R<sup>12</sup> is

H,

halogen,

HO,

R<sup>13</sup>O-,

R<sup>15</sup>R<sup>16</sup>N-,

C1-C3-alkyl,

CF<sub>3</sub>,

R<sup>14</sup>CO<sub>2</sub>-,

R<sup>14</sup>CO-, or

R<sup>14</sup>CONH-;

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 7

R<sup>13</sup> is C1-C3-alkyl;

R<sup>14</sup> is H or C1-C3-alkyl;

R<sup>15</sup> and R<sup>16</sup> are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R<sup>15</sup> and R<sup>16</sup> taken together can be C3-C6-cycloalkyl;

R<sup>17</sup> is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein R<sup>10</sup> and R<sup>11</sup> cannot be both H.

Claim 2 (previously amended): The compound of claim 1 of Formula I wherein one of the substituents of R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, R<sup>13</sup>O-, R<sup>13</sup>S-, halogen, or C1-C3-alkyl;

R<sup>2</sup> and R<sup>3</sup> taken together can be -SCH<sub>2</sub>S-, SCH<sub>2</sub>O-, or -OCH<sub>2</sub>S-;

R<sup>9</sup> is

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 8

$R^{15}R^{16}NCO-$ ,

$R^{15}R^{16}NCS-$ ,

$R^{15}R^{16}N(CR^{17})-$ ,

$R^{17}OCO-$ ,

$R^{15}CO-$ , or

H;

$R^{10}$  and  $R^{11}$  are independently H,  $H_2N-$ , or  $CH_3CONH-$ ; and  
pharmaceutically acceptable salts thereof.

Claim 3 (previously amended): A composition comprising the  
compound of claim 2 and a pharmaceutically acceptable carrier.

Claims 4-7 (canceled)


Claim 8 (previously amended): A composition comprising the  
compound of claim 1 and a pharmaceutically acceptable carrier.

Claim 9 (canceled)

Claim 10 (currently amended): A method for treating a patient  
suffering from ischemia, epilepsy or stroke, the method  
comprising administering to the patient, in an effective amount

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 9

to alleviate the symptoms of the ischemia, epilepsy or stroke, a compound of Formula I:



wherein

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are independently

H,

HO,

R<sup>13</sup>O-,

R<sup>13</sup>S-,

halogen,

C1-C3-alkyl,

CF<sub>3</sub>,

R<sup>14</sup>CO<sub>2</sub>-, R<sup>14</sup>O<sub>2</sub>C-,

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 10

$R^{14}CO-$

$R^{14}CONH-$ ,

$R^{14}NHCO-$ ,

$R^{14}NHCO_2-$ ,

$R^{14}OCONH-$ ,

$R^{14}O_2S-$ ,

$R^{14}OS-$ , or

$R^{15}R^{16}N-$ ; or

$R^1$  and  $R^2$ , or  $R^2$  and  $R^3$ , or  $R^2$  and  $R^4$  taken together can be

$-SCH_2S-$ ,

$-SCH_2O-$ ,

$-OCH_2S-$ ,

$-SCH_2CH_2S-$ ,

$-SCH_2CH_2O-$ , or

$-OCH_2CH_2S-$ ;

wherein one of  $R^1$ ,  $R^2$  and  $R^4$  must be C1-C3-alkoxy or C1-C3-alkylthio group;

$R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  are independently H,

C1-C6-alkyl,

C3-C6-alkenyl, C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is

substituted with one or two substituents, C1-C3-alkyl, halogen,



Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 11

$R^{13}O-$ ,  $CF_3-$ ,  $R^{14}O_2S-$ ,  $R^{14}OS-$ ,  $R^{14}CO-$ ,  $R^{14}CO_2-$ ,  $R^{14}O_2C-$ ,  $R^{14}CONH-$ ,  
 $R^{14}NHCO-$ ; or

$R^9$  and  $R^6$  taken together can be C3-C6-cycloalkyl;

$R^7$  and  $R^8$  taken together can be C3-C6-cycloalkyl;

$R^9$  is

$R^{15}R^{16}NCO-$ ,

$R^{15}R^{16}NCS-$ ,

$R^{15}R^{16}N(CR^{17})-$ ,

$R^{17}OCO-$ ,

$R^{15}CO-$ ,

$R^{15}R^{16}NCH_2CO-$ ,

$R^{14}O_2C-(CH_2)_n-$ ,

$R^{15}R^{16}NCO-(CH_2)_n-$ ,

$NC-(CH_2)_n-$ ,

H,

C1-C6-alkyl, C3-C6-alkenyl, or

C3-C6-cycloalkyl; or

$R^8$  and  $R^9$  taken together can be

$-(CH_2)_mCH_2(R^{15})NCO-$ ,

$-(CH_2)_mCH_2OCO-$ , or

$-(CH_2)_mCH_2CH_2CO-$ ;

$R^{10}$  and  $R^{11}$  are independently H,

Attorney Docket No.:  
Inventors:  
Serial No.:  
Filing Date:  
Page 12

SYM114 (TI-0029)  
Pei et al.  
09/882,843  
June 15, 2001

$R^{15}R^{16}N-$ ,

$R^{15}R^{16}N(CR^{17})-$ ,

$R^{14}HNCO-$ , or

$R^{14}CONH-$ ;

$R^{12}$  is

H,

halogen,

HO,  $R^{13}O-$ ,

$R^{15}R^{16}N-$ ,

C1-C3-alkyl,

$CF_3$ ,

$R^{14}CO_2-$ ,

$R^{14}CO-$ , or

$R^{14}CONH\theta-$ ;

$R^{13}$  is C1-C3-alkyl;

$R^{14}$  is H or C1-C3-alkyl;

$R^{15}$  and  $R^{16}$  are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 13

$R^{15}$  and  $R^{16}$  taken together can be C3-C6-cycloalkyl;

$R^{17}$  is C1-C6-alkyl, C3-C6-alkenyl, or C3-C6-cycloalkyl;

n is 1 to 6;

m is 0 to 2;

and pharmaceutically acceptable salts thereof;

wherein  $R^{10}$  and  $R^{11}$  cannot be both H,

in combination with a pharmaceutically acceptable carrier.

Claim 11 (currently amended): The method of claim 10 wherein, in the compound of Formula I, one of the substituents of  $R^1$ ,  $R^3$  and  $R^4$  must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H,  $R^{13}O-$ ,  $R^{13}S-$ , halogen, or C1-C3-alkyl;  $R^2$  and  $R^3$  taken together can be  $-SCH_2S-$ ,  $-SCH_2O-$ , or  $-OCH_2S-$ ;

$R^9$  is

$R^{15}R^{16}NCO-$ ,

$R^{15}R^{16}NCS-$ ,

$R^{15}R^{16}N(CR^{17})-$ ,

$R^{17}OCO-$ , or

$R^{15}CO-$ , or

H;


$R^{10}$  and  $R^{11}$  are independently H,  $H_2N-$ , or  $CH_3CONH-$ ; and

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 14

pharmaceutically acceptable salts thereof.

Claim 12-15 (canceled)

Claim 16 (currently amended): A compound of Formula II:



wherein

R<sup>1</sup> and R<sup>4</sup> are independently

H,

HO,

R<sup>13</sup>O-

R<sup>13</sup>S-

halogen,

Attorney Docket No.: SYM114 (TI-0029)  
 Inventors: Pei et al.  
 Serial No.: 09/882,843  
 Filing Date: June 15, 2001  
 Page 15

C1-C3-alkyl,  $\text{CF}_3$ ,  $\text{R}^{14}\text{CO}_2^-$ ,  $\text{R}^{14}\text{O}_2\text{C}-$ ,

$\text{R}^{14}\text{CO}-$

$\text{R}^{14}\text{CONH}-$ ,

$\text{R}^{14}\text{NHCO}-$ ,

$\text{R}^{14}\text{NHCO}_2-$ ,

$\text{R}^{14}\text{OCONH}-$ ,

$\text{R}^{14}\text{O}_2\text{S}-$ ,

$\text{R}^{14}\text{OS}-$ , or

$\text{R}^{15}\text{R}^{16}\text{N}-$ ; or

$\text{R}^2$  is one of H, HO,  $\text{R}^{13}\text{O}$ , halogen, C1-C3-alkyl,  $\text{CF}_3$ ,  $\text{R}^{14}\text{CO}_2^-$ ,  $\text{R}^{14}\text{O}_2\text{C}-$ ,  $\text{R}^{14}\text{CO}-$ ,  $\text{R}^{14}\text{CONH}-$ ,  $\text{R}^{14}\text{NHCO}-$ ,  $\text{R}^{14}\text{NHCO}_2-$ ,  $\text{R}^{14}\text{OCONH}-$ ,  $\text{R}^{14}\text{O}_2\text{S}-$ ,  $\text{R}^{14}\text{OS}-$ ,  $\text{R}^{13}\text{S}-$  and  $\text{R}^{15}\text{R}^{16}\text{N}-$  when  $\text{R}^2$  is one of HO, halogen, C1-C3-alkyl,  $\text{CF}_3$ ,  $\text{R}^{14}\text{CO}_2^-$ ,  $\text{R}^{14}\text{O}_2\text{C}-$ ,  $\text{R}^{14}\text{CO}-$ ,  $\text{R}^{14}\text{CONH}-$ ,  $\text{R}^{14}\text{NHCO}-$ ,  $\text{R}^{14}\text{NHCO}_2-$ ,  $\text{R}^{14}\text{OCONH}-$ ,  $\text{R}^{14}\text{O}_2\text{S}-$ ,  $\text{R}^{14}\text{OS}-$ ,  $\text{R}^{13}\text{S}-$  and  $\text{R}^{15}\text{R}^{16}\text{N}-$ ; or

$\text{R}^2$  is one of H, HO, halogen, C1-C3-alkyl,  $\text{CF}_3$ ,  $\text{R}^{14}\text{CO}_2^-$ ,  $\text{R}^{14}\text{O}_2\text{C}-$ ,  $\text{R}^{14}\text{CO}-$ ,  $\text{R}^{14}\text{CONH}-$ ,  $\text{R}^{14}\text{NHCO}-$ ,  $\text{R}^{14}\text{NHCO}_2-$ ,  $\text{R}^{14}\text{OCONH}-$ ,  $\text{R}^{14}\text{O}_2\text{S}-$ ,  $\text{R}^{14}\text{OS}-$ ,  $\text{R}^{13}\text{S}-$  and  $\text{R}^{15}\text{R}^{16}\text{N}-$  when  $\text{R}^3$  is one of H, HO,  $\text{R}^{13}\text{O}$ , halogen, C1-C3-alkyl,  $\text{CF}_3$ ,  $\text{R}^{14}\text{CO}_2^-$ ,  $\text{R}^{14}\text{O}_2\text{C}-$ ,  $\text{R}^{14}\text{CO}-$ ,  $\text{R}^{14}\text{CONH}-$ ,  $\text{R}^{14}\text{NHCO}-$ ,  $\text{R}^{14}\text{NHCO}_2-$ ,  $\text{R}^{14}\text{OCONH}-$ ,  $\text{R}^{14}\text{O}_2\text{S}-$ ,  $\text{R}^{14}\text{OS}-$ ,  $\text{R}^{13}\text{S}-$  and  $\text{R}^{15}\text{R}^{16}\text{N}-$ ; or

$\text{R}^1$  and  $\text{R}^2$ , or  $\text{R}^2$  and  $\text{R}^3$ , or  $\text{R}^2$  and  $\text{R}^4$  taken together can be

$-\text{SCH}_2\text{S}-$ ,

$-\text{SCH}_2\text{O}-$ ,

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 16

-OCH<sub>2</sub>S-,

-SCH<sub>2</sub>CH<sub>2</sub>S-,

-SCH<sub>2</sub>CH<sub>2</sub>O-, or

-OCH<sub>2</sub>CH<sub>2</sub>S-;

wherein one of the substituents of R<sup>1</sup>, R<sup>3</sup> and R<sup>5</sup> must be C1-C3-alkoxy or C1-C3-alkylthio group;

R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> and R<sup>8</sup> are independently

H, C1-C6-alkyl,

C3-C6-alkenyl, C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, R<sup>13</sup>O-, CF<sub>3</sub>-, R<sup>14</sup>O<sub>2</sub>S-, R<sup>14</sup>OS-, R<sup>14</sup>CO<sub>2</sub>-, R<sup>14</sup>CO<sub>2</sub>-, R<sup>14</sup>O<sub>2</sub>C-, R<sup>14</sup>CONH-,

R<sup>14</sup>NHCO<sub>2</sub>-; or

R<sup>5</sup> and R<sup>6</sup> taken together can be C3-C6-cycloalkyl;

R<sup>13</sup> is C1-C3-alkyl;

R<sup>14</sup> is H or C1-C3-alkyl;

R<sup>15</sup> and R<sup>16</sup> are independently

H, C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R<sup>15</sup> and R<sup>16</sup> taken together can be C3-C6-cycloalkyl;

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 17

R<sup>18</sup> and R<sup>19</sup> are independently

H,

halogen,

C1-C3-alkyl,

R<sup>14</sup>O-,

CF<sub>3</sub>-, or

R<sup>14</sup>CO<sub>2</sub>-;

R<sup>20</sup> and R<sup>21</sup> are independently

H,

R<sup>15</sup>R<sup>16</sup>N-,

R<sup>15</sup>HNC(NH) - or

R<sup>14</sup>CONH-;

and pharmaceutically acceptable salts thereof;

wherein R<sup>20</sup> and R<sup>21</sup> cannot both be H.

Claim 17 (previously amended): The compound of claim 16 of Formula II wherein one of the substituents of R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, R<sup>11</sup>O-, R<sup>11</sup>S-, halogen, or C1-C3-alkyl;

R<sup>2</sup> and R<sup>3</sup> taken together can be -SCH<sub>2</sub>S-, -SCH<sub>2</sub>O-, or -OCH<sub>2</sub>S-;

R<sup>20</sup> and R<sup>21</sup> are independently H, H<sub>2</sub>N-, or CH<sub>3</sub>CONH-; and

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 18

pharmaceutically acceptable salts thereof.

Claim 18 (previously amended): A composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier.

Claims 19-22 (canceled)


Claim 23 (previously amended): A composition comprising the compound of claim 16 and a pharmaceutically acceptable carrier.

Claim 24 (canceled)

Claim 25 (currently amended): A method for treating a patient, the method comprising administering to the patient, in an effective amount to alleviate the symptoms of the ischemia, epilepsy or stroke, a compound of Formula II:



Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 19



wherein

R<sup>1</sup> and R<sup>4</sup> are independently

H,

HO,

R<sup>13</sup>O-,

R<sup>13</sup>S-,

halogen,

C1-C3-alkyl,

CF<sub>3</sub>,

R<sup>14</sup>CO<sub>2</sub>-,

R<sup>14</sup>O<sub>2</sub>C-,

R<sup>14</sup>CO-

R<sup>14</sup>CONH-,

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 20

$R^{14}NHCO-$ ,

$R^{14}NHCO_2-$ ,

$R^{14}OCONH-$ ,

$R^{14}O_2S-$ ,

$R^{14}OS-$ , or

$R^{15}R^{16}N-$ ; or

$R^2$  is one of H, HO,  $R^{13}O$ , halogen, C1-C3-alkyl,  $CF_3$ ,  $R^{14}CO_2-$ ,  $R^{14}O_2C-$ ,  $R^{14}CO-$ ,  $R^{14}CONH-$ ,  $R^{14}NHCO-$ ,  $R^{14}NHCO_2-$ ,  $R^{14}OCONH-$ ,  $R^{14}O_2S-$ ,  $R^{14}OS-$  and  $R^{15}R^{16}N-$  when  $R^3$  is one of HO, halogen, C1-C3-alkyl,  $CF_3$ ,  $R^{14}CO_2-$ ,  $R^{14}O_2C-$ ,  $R^{14}CO-$ ,  $R^{14}CONH-$ ,  $R^{14}NHCO-$ ,  $R^{14}NHCO_2-$ ,  $R^{14}OCONH-$ ,  $R^{14}O_2S-$ ,  $R^{14}OS-$ ,  $R^{13}S-$  and  $R^{15}R^{16}N-$ ; or

$R^2$  is one of H, HO, halogen, C1-C3-alkyl,  $CF_3$ ,  $R^{14}CO_2-$ ,  $R^{14}O_2C-$ ,  $R^{14}CO-$ ,  $R^{14}CONH-$ ,  $R^{14}NHCO-$ ,  $R^{14}NHCO_2-$ ,  $R^{14}OCONH-$ ,  $R^{14}O_2S-$ ,  $R^{14}OS-$  and  $R^{15}R^{16}N-$  when  $R^3$  is one of H, HO,  $R^{13}O$ , halogen, C1-C3-alkyl,  $CF_3$ ,  $R^{14}CO_2-$ ,  $R^{14}O_2C-$ ,  $R^{14}CO-$ ,  $R^{14}CONH-$ ,  $R^{14}NHCO-$ ,  $R^{14}NHCO_2-$ ,  $R^{14}OCONH-$ ,  $R^{14}O_2S-$ ,  $R^{14}OS-$ ,  $R^{13}S-$  and  $R^{15}R^{16}N-$ ; or

$R^1$  and  $R^2$ , or  $R^2$  and  $R^3$ , or  $R^3$  and  $R^4$  taken together can be

$-SCH_2S-$ ,

$-SCH_2O-$ ,

$-OCH_2S-$ ,

$-SCH_2CH_2S-$ ,

$-SCH_2CH_2O-$ , or

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 21

-OCH<sub>2</sub>CH<sub>2</sub>S-;

wherein one of the substituents of R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> must be C1-C3-alkoxy or C1-C3-alkylthio group;

R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup> are independently

H,

C1-C6-alkyl,

C3-C6-alkenyl,

C3-C6-cycloalkyl,

phenyl or substituted phenyl, wherein the phenyl is substituted with one or two substituents, C1-C3-alkyl, halogen, R<sup>13</sup>O-, CF<sub>3</sub>-, R<sup>14</sup>O<sub>2</sub>S-, R<sup>14</sup>OS-, R<sup>14</sup>CO<sub>2</sub>-, R<sup>14</sup>CO<sub>2</sub>-, R<sup>14</sup>O<sub>2</sub>C-, R<sup>14</sup>CONH-, R<sup>14</sup>NHCO<sub>2</sub>-; or

R<sup>5</sup> and R<sup>6</sup> taken together can be C3-C6-cycloalkyl;

R<sup>13</sup> is C1-C3-alkyl;

R<sup>14</sup> is H or C1-C3-alkyl;

R<sup>15</sup> and R<sup>16</sup> are independently

H,

C1-C10-alkyl,

C1-C6-perfluoroalkyl,

C3-C10-alkenyl, or

C3-C6-cycloalkyl; or

R<sup>15</sup> and R<sup>16</sup> taken together can be C3-C6-cycloalkyl;

R<sup>18</sup> and R<sup>19</sup> are independently

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 22

H,

halogen,

C1-C3-alkyl,

R<sup>14</sup>O-,

CF<sub>3</sub>- CF<sub>3</sub>-, or

R<sup>14</sup>CO<sub>2</sub>-;

R<sup>20</sup> and R<sup>21</sup> are independently

H,

R<sup>15</sup>R<sup>16</sup>N-,

R<sup>15</sup>HNC(NH) - or

R<sup>14</sup>CONH-;

and pharmaceutically acceptable salts thereof;

wherein R<sup>20</sup> and R<sup>21</sup> cannot both be H.

in combination with a pharmaceutically acceptable carrier.

Claim 26 (previously amended): The method of claim 25 wherein, in the compound of Formula II wherein one of the substituents of R<sup>1</sup>, R<sup>3</sup> and R<sup>4</sup> must be C1-C3-alkylthio group or C1-C3-alkoxy group, the other substituents are independently H, R<sup>13</sup>O-, R<sup>13</sup>S-, halogen, or C1-C3-alkyl;

R<sub>2</sub> and R<sub>3</sub> taken together can be -SCH<sub>2</sub>S-, -SCH<sub>2</sub>O-, or -OCH<sub>2</sub>S-;

R<sup>20</sup> and R<sup>21</sup> are independently H, H<sub>2</sub>N-, or CH<sub>3</sub>CONH-; and

Attorney Docket No.: SYM114 (TI-0029)  
Inventors: Pei et al.  
Serial No.: 09/882,843  
Filing Date: June 15, 2001  
Page 23

pharmaceutically acceptable salts thereof.

Claims 27-30 (canceled)